Progress Toward the Cure of Rheumatoid Arthritis? The BeSt Study
|
|
- Alberta Goodman
- 6 years ago
- Views:
Transcription
1 ARTHRITIS & RHEUMATISM Vol. 52, No. 11, November 2005, pp DOI /art , American College of Rheumatology EDITORIAL Progress Toward the Cure of Rheumatoid Arthritis? The BeSt Study Michael H. Weisman It is remarkable how the treatment of rheumatoid arthritis (RA) has changed over the past decades. In 1975, when this author began his academic practice, rheumatologists often did not use the word treatment. We talked about managing the patient, not treating the disease, and we certainly were cautious, indeed tentative, in the management of early disease. The word cure was absent from our lexicon. We dared not to combine our drugs how could you tell which one was working or which one was responsible for the side effects? We even worried that some of our drugs such as high-dose corticosteroids were causing the common and sometimes life-threatening vasculitic complications of RA. Now, rheumatologists often speak of remission and we hardly ever see vasculitis and other severe systemic manifestations in RA patients. Therefore, it is important to put into perspective a provocative and very creative study of RA treatment by Goekoop-Ruiterman et al, reported in this issue of Arthritis & Rheumatism, with the acronym BeSt (a Dutch acronym for Behandel- Strategieën, or treatment strategies ) (1). This study compares treatment strategies that aggressively treat early-onset RA with combinations of drugs (even including high doses of steroids), a study that likely will change our management of RA even more! How and why did we get here? The BeSt study: what did it show? The BeSt study is a single-blind, multicenter randomized clinical trial comparing 4 treatment strategies: sequential substitution monotherapy (for treatment Michael H. Weisman, MD, FACP, FACR: Cedars-Sinai Medical Center, Los Angeles, California. Dr. Weisman has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Amgen, Bristol-Myers Squibb, Centocor, Isis, Pfizer, Roche, and TAP. Address correspondence and reprint requests to Michael H. Weisman, MD, FACP, FACR, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, B-122, Los Angeles, CA weisman@cshs.org. Submitted for publication June 22, 2005; accepted in revised form August 9, group 1), step-up add-on combination therapy (for treatment group 2), initial combination therapy with a short course of high-dose prednisone (for treatment group 3), and initial combination therapy with the tumor necrosis factor (TNF) antagonist infliximab (for treatment group 4). The study had a common goal for all 4 strategies, namely, to obtain a clinically significant low level of disease activity (a Disease Activity Score in 44 joints [DAS 44 ]of 2.4) (2) with intensive monitoring every 3 months, at which time the treating physician immediately adjusted therapy by a preset algorithm to a more intensive regimen if treatment failed to result in a DAS 44 of 2.4. Alternatively, if a patient achieved an adequate response (a DAS 44 of 2.4) for 6 consecutive months from any of the 4 regimens, the drugs were subsequently tapered in a preset manner to a maintenance dose of monotherapy. Prednisone and infliximab were always the first drugs to be tapered to zero. If a patient had a disease flare after a drug taper, that drug was reintroduced at the last effective dose. Prednisone could be reintroduced only once. Primary end points were the Dutch version of the Health Assessment Questionnaire (3) and radiographic damage assessed according to the modified Sharp/Van der Heijde score (SHS) (4). All patients were evaluated by research nurses blinded to treatment assignment; the research nurse calculated the DAS 44 every 3 months and made the decision of whether to adjust medications. Radiographs were scored paired, in random order, and independently by 2 assessors. The results of the study were very impressive. Five hundred eight patients with very early RA were evenly balanced after randomization; these patients had active (mean SD DAS 44 of ), early (median duration of symptoms of 23 weeks), and severe (72% had erosions) disease at baseline. The 2 combination therapy groups achieved a sustained low DAS 44 and functional improvement more rapidly than did the groups receiving sequential monotherapy or step-up combination therapy. At 1 year of followup, patients treated with both initial combinations had less progres- 3326
2 EDITORIAL 3327 sion of radiographic damage than did the groups receiving sequential monotherapy or step-up combination therapy. Did the group receiving initial combination therapy with infliximab display more success in limiting radiographic progression than the group receiving initial combination therapy with prednisone? Table 2 and Figure 4 in the article by Goekoop-Ruiterman et al indicate a numeric (but not statistically significant) advantage of the infliximab group at 1 year. However, a subanalysis of only patients without erosive disease at baseline revealed that the combination with infliximab was more successful than the combination with prednisone in terms of preventing the development of new erosions at 1 year (P 0.028). Toxic effects were not different among the groups. The goal of the BeSt investigators was to find the optimum strategy to prevent damage and preserve function through real-world regimens frequently employed by rheumatologists. The authors note the marked improvement in all groups at the end of 1 year (one-third of the entire cohort achieved remission of their disease, defined as a DAS 44 of 1.6); they attribute this to the tight control achieved by close monitoring and immediate dose adjustments. The authors provide 3 important observations derived from their efforts: 1) tight control allowed 40% of patients in groups 1 and 2 treated with methotrexate (MTX) alone to achieve a sustained suppression of disease activity; 2) the differences in radiographic progression scores at 1 year, although statistically significant, were small from a clinical perspective; and 3) patients in groups 3 and 4 had more rapid relief of symptoms and improvement in function. The authors describe both an argument and a counterargument arising from their observations: aggressive treatment with combinations of expensive drugs would overtreat a large proportion of patients, yet early suppression of disease activity may have an important influence on subsequent long-term disability and damage. What are the challenges coming from the BeSt study? Rheumatologists have to confront several challenges from the BeSt study almost on a daily basis in our practice. Do we treat patients aggressively, which ones, and with what agents? Do we overtreat some patients to get the greatest benefit for all? What is the role of steroids? How do we interpret radiographic data showing change in the SHS and their potential clinical significance? Have the BeSt researchers moved the field forward, and in what way? In order to address these issues, the following 4 questions will be asked of the literature in general and the BeSt doctors in particular. 1. Do combinations of drugs in established disease provide more clinical and radiographic benefit than single drugs alone? 2. Is there a window of opportunity to treat early RA? Is aggressive treatment more beneficial than a conservative or gradualist approach in the long run, with the possibility of affecting the important outcome of mortality? 3. Should corticosteroids be part of an early aggressive approach? Do corticosteroids do more good than harm, and is there a safe steroid regimen? 4. Do targeted biologic agents yield radiographic improvement out of proportion to control of inflammation? Is it because of their unique mechanism of action? Do combinations of drugs in established disease achieve a greater clinical and radiographic benefit compared with single agents alone? This part of the story begins with a 1987 report by Scott and colleagues (5) revealing that more than half of 100 RA patients at a London teaching hospital were either dead or severely disabled after 20 years of modern treatment. This study confirmed the dismal state of RA treatment in the 1980s. Cognizant of the emerging and successful use of MTX in the US over the same time period, Wilske and Healey suggested, 2 years later, in 1989 (6), that we must change our approach. Their reported method (without any data to back it up at the time) suggested that rheumatologists should act like oncologists (i.e., treat all patients with full-dose combinations of drugs at the outset, then sequentially withdraw the most toxic ones, leaving patients to receive maintenance therapy with the most benign compound). In their report, Wilske and Healey recognized that multiple drugs have different mechanisms of action, and they proposed that a combination of agents employed at a critical stage of inflammation could have a longlasting effect on bone and joint integrity. It took a full 7 years before O Dell and colleagues (7) provided the data to support the method of Wilske and Healey. O Dell and colleagues were able to demonstrate convincingly that combinations of conventional disease-modifying antirheumatic drugs (DMARDs) were more effective than and just as safe as single agents in the treatment of established disease. Currently, and with the use of the anti-tnf biologic agents, this
3 3328 WEISMAN hypothesis has been shown to be true in multiple studies revealing that a biologic agent can provide additional and clinically significant benefit to that already achieved with MTX alone in established disease (8 10). Does the BeSt study add anything to answer this question? Yes, but only indirectly, since the BeSt researchers addressed this question in early, but not in established, disease. The combination of standard DMARD agents at the outset (although with corticosteroids) did show more rapid clinical improvement and a more favorable radiographic result either compared with tight control with sequential monotherapy or compared with tight control with step-up combination therapy. A direct comparison of the latter 2 strategies disclosed no difference between them either in clinical or in radiographic outcome. The BeSt data confirm prior experience (11) that the combination of sulfasalazine (SSZ) and MTX has little or no additive therapeutic effect; combining them was no better than switching in the BeSt trial. Therefore, it appears that the optimal use of a combination should be at the outset, and not later. The BeSt researchers make the point that starting with a single DMARD is a missed opportunity. Is there a window of opportunity to treat RA? Is aggressive treatment more beneficial in the long run with the possibility of affecting the important outcome of mortality? A study of patients with early arthritis performed in Manchester, UK, using the technique of propensity scoring as a method of adjusting for disease severity in observational cohorts (12), revealed that institution of standard DMARD regimens within the first 6 months of disease reduced the amount of radiographic damage at 5 years compared with institution of these same drugs later. Lard et al compared the effects of delayed and early treatment strategies in successive cohorts of patients with early RA; a smaller area under the curve (AUC) of disease activity as well as a reduced Sharp radiographic score were seen in the early treatment strategy group (13). In the TICORA (tight control for rheumatoid arthritis) study, when patients with earlyonset disease were randomly assigned to tight control employing an aggressive and intensive outpatient disease management program (even including liberal use of systemic corticosteroids) and compared with patients receiving usual rheumatologic care, the employment of aggressive management had greater effects on disease activity as well as on subsequent joint damage (14). All of these data appear to solidly support the conclusion reached by the BeSt investigators that early aggressive treatment has significant long-term benefits. Changes in the early mortality typically attributed to RA give further testimony to the benefit of early institution of aggressive management. A very large community-based observational cohort assembled by Mitchell and coworkers in the 1970s and 1980s (15) revealed that the survival rate of RA patients was reduced substantially (50%) compared with populationmatched controls. In addition to the traditional influence on mortality from demographic variables of age and male sex, multivariate analysis identified baseline variables reflecting disease activity and severity (functional class, rheumatoid factor [RF] titer, number of involved joints) that independently influenced survival. The separation of mortality from that in the comparator population occurred almost immediately in this cohort. The experience of the Mayo Clinic was similar, as reported by Gabriel and colleagues (16). Mortality in RA patients occurred early in the disease course and did not improve in successive cohorts assembled from 1955 to 1985 in spite of improved survival of the age- and sex-matched Rochester, MN residents during this exact time frame. Dr. Gabriel already knew the negative answer to the question when she titled her article Mortality in rheumatoid arthritis: have we made an impact in 4 decades? However, mortality data from an inception cohort beginning in 1985 reflecting early, aggressive, and sustained DMARD treatment tell a different story. As shown in Figure 1, Kroot and colleagues (17) were able to show that in 622 patients followed up over 10 years, mortality did not differ from that in age- and sexmatched controls from the general population of The Netherlands. The usual baseline disease severity and activity characteristics such as RF status, functional capacity, and disease activity were not statistically significant predictors of death, suggesting that treatment may have had an important influence on this result. Even recently published mortality data (Figure 2) from Gabriel and colleagues at the Mayo Clinic (18) reveal that the separation of mortality in RA patients from that in the comparator population really does not take place until well after 5 years of disease, and male sex was no longer a risk factor for death in the Mayo Clinic population. Whether these improving mortality data can be attributed to a reduction in cigarette smoking or other changes in ambient care remains unclear; however, an aggressive disease management approach in patients diagnosed earlier as having RA cannot be discounted. The BeSt study may be right on target here.
4 EDITORIAL 3329 Figure 1. Kaplan-Meier survival curve of 622 patients with recentonset rheumatoid arthritis compared with that of age- and sex-matched controls from the general population of The Netherlands. Error bars indicate 95% confidence intervals of the study group. Adapted, with permission, from ref. 17. Should corticosteroids be part of an early aggressive approach? Do corticosteroids do more good than harm, and is there a safe steroid regimen? The successful employment of high-dose prednisone with a rapid taper in 1 of the 4 treatment arms of the BeSt study brings the steroid issue sharply into focus. It is possible that an initial pulse of corticosteroids at a critical time (the early window) may do more good than harm. Nevertheless, most rheumatologists, appropriately, have difficulty accepting prolonged corticosteroid use as an ongoing management strategy. Although many rheumatologists would be reluctant to believe it, corticosteroids have been shown to have a disease-modifying effect when the right dose and comparator populations are selected. Two largely forgotten studies from the UK in a population of patients with early RA (disease duration 3 24 months) were reported 45 years ago; the group that received only nonsteroidal antiinflammatory drugs displayed worsening of disease in terms of radiographic progression compared with the group that received prednisolone, with a statistically significant difference extending for 4 years of followup (19 21). Decades later in the UK, Kirwan further established the disease-modifying potential of corticosteroids by demonstrating a substantial decrease in erosion score as well as in newly eroded joints from the administration of 7.5 mg/day prednisolone compared with placebo in a cohort of patients with early RA (22). Similar data have come from The Netherlands in studies by Van Everdingen et al (23) in a cohort of patients newly diagnosed as having RA. Lowdose oral glucocorticoids as monotherapy resulted in an initial clinical effect that was not sustained, yet there was significantly less radiographic progression in the steroidtreated group. Do these low-dose steroid therapies cause unacceptable bone loss? On the one hand, a later followup of the Dutch cohort revealed osteoporotic fractures to have supervened more frequently in the steroid-treated group (24). On the other hand, a recently reported followup analysis of Kirwan s UK cohort revealed that diseaserelated hand bone loss (measured by digital x-ray radiogrammetry) actually decelerated as a result of prednisolone treatment (compared with placebo) at both 1- and 2-year time points (25). The controversy continues. Further support for the use of a high-dose and rapid-taper steroid regimen comes from the COBRA (Combinatietherapie Bij Reumatoïde Artritis) trial, a 2-arm, step-down bridge study that compared a combination of SSZ, MTX, and high-dose prednisolone with SSZ alone in a cohort of patients with early RA (26). Although the clinical difference between the 2 treatment arms was no longer present once the corticosteroids were tapered and discontinued, the radiographic benefit has persisted for 4 5 years of followup (27). What can we conclude about steroids from these studies, and do the BeSt data provide us with an additional perspective? The BeSt data support the concept that in early, active RA, the use of a high-dose regimen with a rapid taper will result in a longer term residual radiographic benefit once the steroids are gone. How high is high and how long can it be given? If it is true that extended followup of these short-course high- Figure 2. Observed survival rate among 609 Rochester, MN residents first diagnosed as having rheumatoid arthritis (RA) between January 1, 1955 and December 31, 1994, compared with expected survival rate (P 0.001). Adapted from ref. 18.
5 3330 WEISMAN dose and rapid-taper steroid-treated patients does not reveal problematic bone loss or fractures, a BeSt/ COBRA regimen of 60 mg/day with rapid taper to 7.5 mg/day over 7 weeks may do more good than harm. However, the use of these agents on a longer term maintenance basis continues to be problematic and probably will remain controversial for some time to come. Do targeted biologic agents yield radiographic improvement out of proportion to control of inflammation? Is it because of their unique mechanism of action? Data to answer the above questions are emerging; however, the interpretation is controversial. In the most recent studies examining anti-tnf biologic treatment in early RA in which a comparison is made between the combination (biologic agent and MTX) and MTX alone, the trials with all 3 anti-tnf agents (etanercept, infliximab, and adalimumab) reveal a similar phenomenon (28 30). Figure 3 illustrates changes in the percentage of patients achieving 50% improvement according to the American College of Rheumatology response criteria (an ACR50 response) (31) contrasted with numeric changes in the SHS for all 3 agents. The combination typically results in 50% greater clinical improvement than that gained with MTX alone. In contrast to the ACR50 response, the radiographic outcome with all 3 agents appears to be greatly superior a minimum 4-fold greater improvement is noted with these combinations compared with MTX alone. What remains controversial is the true clinical significance of the magnitude of the changes in the SHS. However, reducing the progression to near zero must not be ignored. Whether these findings are a result of a more rapid benefit achieved with the combination (achieved by an increased AUC) or whether they result from the unique presence of the targeted biologic agent is still a matter of conjecture; the data remain open to interpretation. Along similar lines, the ATTRACT (Anti Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy) investigators (32) have reanalyzed their data comparing infliximab treatment with placebo in RA patients with longstanding disease and an incomplete response to MTX. These investigators have generated the hypothesis that for patients who obtained either little or minimal clinical disease control with either placebo or biologic treatment, those who were treated with infliximab obtained a radiographic benefit. Figure 3. Percentage of patients achieving 50% improvement according to the American College of Rheumatology response criteria (an ACR50 response) (A) and numeric changes in the modified Sharp/Van der Heijde score (SHS) (B) from 3 similarly designed clinical trials in early rheumatoid arthritis (see refs ). Each trial (TEMPO [Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes], ASPIRE [Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset], and PREMIER) compared methotrexate (MTX) monotherapy with the combination (combo) of MTX and an anti tumor necrosis factor agent, and the results at the 1-year time point for each study are displayed. Values in B are the mean. Note the relatively large magnitude of radiographic improvement (B) compared with the more modest clinical improvement shown by the percentages of patients achieving an ACR50 response (A). In other words, for patients with comparable minor clinical improvement as measured by DAS or ACR20 responses, the biologic treatment had a greater effect on inhibition of structural damage. The editorial accompanying the article by Smolen et al in that issue of Arthritis & Rheumatism provides a biologic rationale for these observations by noting that there is an uncoupling of inflammation and radiographic erosion in animal models and in a variety of experimental conditions (33). The authors of the editorial nevertheless suggest that there may be aspects of the ATTRACT trial study design and executed subanalyses that might affect the validity of the conclusions drawn by Smolen et al. Does the BeSt study address this question? The radiographic data in the BeSt trial are consistent with the interpretation that biologics are superior to conventional agents in controlling radiographic progression.
6 EDITORIAL 3331 Although both combination treatment arms yielded clinically equivalent results, a separate analysis examining the patients in the combination treatment arms who did not have erosions at baseline revealed that, compared with the nonbiologic combination, the biologic treatment was more effective in suppressing the development of new erosions at 1 year. Although the question is far from answered definitively, the BeSt data add to the emerging interpretation that early institution of aggressive combination therapy containing targeted biologic agents might possess unique advantages for prevention of radiographic damage. Conclusions Generalizations from clinical trials to clinical practice are always difficult. Take-home messages have to be understood within the context of what the trial was specifically intending to accomplish. Further, we have yet to establish the clinical significance of a change in radiographic SHS with regard to functional disability and quality of life. The whole issue of cost is not addressed since, unless there are changes in health care funding around the world, these treatments are not going to be universally available. Given limited resources and efforts to maximize benefits, how are patients going to be selected for access to these interventions? Nevertheless, we can draw some very real conclusions from our BeSt colleagues; theirs is an outstanding study that will continue to reverberate in the rheumatology community for years to come. The authors should be congratulated for demonstrating the enormous power to be gained from a cooperative study in an organized health care setting. For patients at the time of their initial diagnosis of RA, there appears to be an opportunity to achieve a lasting benefit in their disease course. It may even be possible to create a true clinical remission absent any continuing or ongoing maintenance therapy. BeSt and other strategies tell us that tight control should be accomplished in any case, since most patients appear to do very well under intensive management regardless of the strategy. In early-onset disease, it would be particularly important to further define risk factors for poor outcome so that this group can be selected for aggressive intensive combination treatment containing biologics; if biologics are not available, a high dose and a short course of steroids as part of the combination might suffice. Strategies should continue to be developed to address the question of disease modification. The concept of a DMARD that prevailed in 1975 is now obsolete as we explore, on a molecular level, the relationship between inflammation and destruction. The words remission and cure have crept into our allowable language. We have accomplished a great deal in the past 3 decades. Is prevention possible in the next 3 decades? We re working on it. That would be truly the best solution. ACKNOWLEDGMENTS The author is grateful for the confidence given to him from the Editor, Dr. David Pisetsky, and the longstanding support and wisdom imparted by his mentor, Dr. Nathan Zvaifler. REFERENCES 1. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52: Van der Heijde DM, van t Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20: Siegert CE, Vleming LJ, Vandenbroucke JP, Cats A. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984;3: Van der Heijde DM, van Riel PL, Gribnau FW, Nuverzwart IH, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1: Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1: Wilske KR, Healey LA. Remodeling the pyramid: a concept whose time has come. J Rheumatol 1989;16: O Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334: Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48: Lipsky PE, van der Heijde DM, StClair EW, Furst DE, Breedveld FC, Kalden JR, et al, and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343: Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36: Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a
7 3332 WEISMAN large observational inception study. Arthritis Rheum 2003;48: Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111: Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364: Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29: Gabriel SE, Crowson CS, O Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26: Kroot EJ, van Leeuwen MA, Rijswijk MH, Prevoo ML, van t Hof MA, van de Putte LB, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000;59: Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O Fallon WM, et al. Survival in rheumatoid arthritis: a populationbased analysis of trends over 40 years. Arthritis Rheum 2003;48: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis: a second report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases. Ann Rheum Dis 1959;18: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis: a second report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases. Ann Rheum Dis 1960;19: West HF. Rheumatoid arthritis: the relevance of clinical knowledge to research activities. Abstr World Med 1967;41: Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333: Van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebocontrolled clinical trial. Ann Intern Med 2002;136: Van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW. Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol 2003;21: Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 2005;165: Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [published erratum appears in Lancet 1998;351:220]. Lancet 1997; 350: Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46: Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER investigators. The PREMIER study: combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in methotrexate-naive patients with early, aggressive rheumatoid arthritis. Arthritis Rheum. In press. 29. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, and the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363: StClair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50: Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study. Arthritis Rheum 2005;52: Van den Berg WB, van Riel PL. Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality? [editorial]. Arthritis Rheum 2005;52:995 9.
The BeSt way of withdrawing biologic agents
The BeSt way of withdrawing biologic agents C.F. Allaart 1, W.F. Lems 2, T.W.J. Huizinga 1 1 Department of Rheumatology, Leiden University Medical Center, Leiden; 2 Department of Rheumatology, Free University
More informationStructural damage in rheumatoid arthritis as visualized through radiographs Désirée van der Heijde
Structural damage in rheumatoid arthritis as visualized through radiographs Désirée van der Heijde University Hospital Maastricht, Maastricht, The Netherlands; and Limburg University Center, Diepenbeek,
More informationAppendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months
Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20644 holds various files of this Leiden University dissertation. Author: Klarenbeek, Naomi Bertine Title: Targeted treatment in early rheumatoid arthritis
More informationRelative effect (95% CI) RR LOW 2,3 due to indirectness, imprecision. RR 1.45 (0.43 to 4.84) due to indirectness, imprecision. (0.18 to 20.
Appendix: Evidence Reports Question In patients with early RA with moderate or high disease activity, who are DMARD-naive, what is the impact of combination double DMARD therapy vs. mono-dmard therapy
More informationBenefit/risk of combination therapies
Benefit/risk of combination therapies D. Zerkak, M. Dougados Rheumatology B Department, Cochin Hospital, René Descartes University, Paris, France. Djamila Zerkak, MD; Maxime Dougados, MD. Please address
More informationR heumatoid arthritis (RA) is a chronic autoimmune
274 EXTENDED REPORT Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis J van Aken, L R Lard, S le Cessie, J M W Hazes, F
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationR heumatoid arthritis (RA) is a chronic autoimmune
274 EXTENDED REPORT Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis J van Aken, L R Lard, S le Cessie, J M W Hazes, F
More informationJ. van Aken* H. van Dongen* S. le Cessie F.C. Breedveld T.W.J. Huizinga. * both authors contributed equally
CHAPTER Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study J. van Aken* H. van
More informationCombination therapy in. rheumatoid arthritis
Chapter 2 Combination therapy in rheumatoid arthritis YPM Goekoop CF Allaart FC Breedveld BAC Dijkmans Curr Opin Rheumatol 2001;13:177-83. ABSTRACT It has become clear that early suppression of rheumatoid
More informationSuperior Efficacy of Combination Therapy for Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 52, No. 10, October 2005, pp 2975 2983 DOI 10.1002/art.21293 2005, American College of Rheumatology REVIEW Superior Efficacy of Combination Therapy for Rheumatoid Arthritis
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationThe Journal of Rheumatology Volume 41, no. 2
The Volume 41, no. 2 Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study Edward C. Keystone,
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationThe Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 63, No. 5, May 2011, pp 1200 1210 DOI 10.1002/art.30263 2011, American College of Rheumatology The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results
More informationThe long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study
RHEUMATOLOGY Rheumatology 2011;50:1106 1110 doi:10.1093/rheumatology/keq424 Advance Access publication 21 January 2011 Concise report The long-term impact of early treatment of rheumatoid arthritis on
More informationORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION
Arthritis Care & Research Vol. 63, No. 1, January 2011, pp 128 134 DOI 10.1002/acr.20331 2011, American College of Rheumatology ORIGINAL ARTICLE American College of Rheumatology Hybrid Analysis of Certolizumab
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationInitial High-Dose Prednisolone Combination Therapy Using COBRA and COBRA-Light in Early Rheumatoid Arthritis
Efficacy of Low-Dose Glucocorticoids in Clinical Trials Neuroimmunomodulation 2015;22:5156 Published online: September 12, 2014 Initial High-Dose Prednisolone Combination Therapy Using COBRA and COBRA-Light
More informationMETHODS In the context of an indirect comparison metaanalysis between tocilizumab and other biological
c Additional data are published online only at http://ard.bmj. com/content/vol69/issue1 Correspondence to: Professor M Boers, Department of Epidemiology and Biostatistics, VU University Medical Centre,
More informationOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
RHEUMATOLOGY Rheumatology 2012;51:v12 v21 doi:10.1093/rheumatology/kes111 Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs Karel
More informationR heumatoid arthritis is a chronic inflammatory disease with
1443 EXTENDED REPORT Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationCLINICAL BRIEFS. Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases
CLINICAL BRIEFS Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases A review of immunogenicity and potential implications By Joseph Flood, MD, FACR President, Musculoskeletal
More informationF or the management of rheumatoid arthritis, there is
1294 EXTENDED REPORT Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial J Fransen, H Bernelot Moens, I
More informationTumor Necrosis Factor Therapy and the Risk of Serious Infection and Malignancy in Patients With Early Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 63, No. 6, June 2011, pp 1479 1485 DOI 10.1002/art.30310 2011, American College of Rheumatology Tumor Necrosis Factor Therapy and the Risk of Serious Infection and Malignancy
More informationBringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationImproving the Routine Management of Rheumatoid Arthritis: The Value of Tight Control
The Improving the Routine Management of Rheumatoid Arthritis: The Value of Tight Control Philip J. Mease DOI: 10.3899/jrheum.091064 http://www.jrheum.org/content/early/2010/06/28/jrheum.091064 1. Sign
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/24405 holds various files of this Leiden University dissertation. Author: Wevers- de Boer, Kirsten Vera Caroline Title: Improving disease outcomes in early
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationThe medical treatment of rheumatoid arthritis has been dramatically improved with the
DOI: 10.5124/jkma.2010.53.10.871 pissn: 1975-8456 eissn: 2093-5951 http://jkma.org Focused Issue of This Month Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease
More informationOpen Access NY, USA. Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal.
Send Orders for Reprints to reprints@benthamscience.net 58 The Open Rheumatology Journal, 2013, 7, 58-63 Open Access The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28
More informationGlucocorticoid treatment in early rheumatoid arthritis
Glucocorticoid treatment in early rheumatoid arthritis D. Krause 1, R. Rau 2, J. Braun 3 1 Internistische und Rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, and Abteilung für Medizinische Informatik,
More informationThe Relationship Between Disease Activity and Radiologic Progression in Patients With Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 50, No. 7, July 2004, pp 2082 2093 DOI 10.1002/art.20350 2004, American College of Rheumatology The Relationship Between Disease Activity and Radiologic Progression in Patients
More informationThis is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors..
This is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/118272/ Version: Accepted
More informationA non-inferiority trial of an attenuated combination strategy ( COBRA-light ) compared to the original COBRA strategy: clinical results after 26 weeks
2 A non-inferiority trial of an attenuated combination strategy ( COBRA-light ) compared to the original COBRA strategy: clinical results after 26 weeks Debby den Uyl*, Marieke M. ter Wee*; Maarten Boers,
More information46 Resurgence of Low Dose Steroids in
46 Resurgence of Low Dose Steroids in Management of Rheumatoid Arthritis RN Sarkar Abstract: The depressing description of rheumatoid arthritis described by Sir William Osler has changed dramatically due
More informationRecommendations for RA management: what has changed?
The 2016 Update of the EULAR Recommendations for RA management: what has changed? Baltics Rheumatology Conference Vilnius, September 21-22 Prof. Diego Kyburz University Hospital of Basel Switzerland Multiple
More informationChapter 4. Advances in Rheumatology 2004 volume 2
Chapter 4 Sustained remission in a cohort of patients with rheumatoid arthritis: association with absence of IgM rheumatoid factor and absence of anti-ccp antibodies. Advances in Rheumatology 2004 volume
More informationABSTRACT Background. Methods. Results. Conclusions
Chapter 3 Clinical response to adalimumab: the relationship with antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis G.M. Bartelds C.A. Wijbrandts M.T. Nurmohamed S. Stapel
More informationCross-validation of a clinical pharmacogenetic model to predict the efficacy of MTX monotherapy in established
Chapter 5: Cross-validation of a clinical pharmacogenetic model to predict the efficacy of MTX monotherapy in established RA Jaap Fransen 1, Wouter M. Kooloos 2, Judith AM Wessels 2, Tom WJ Huizinga 3,
More informationRheumatoid arthritis: More aggressive approach improves outlook
MEDICAL GRAND ROUNDS CME CREDIT TAKE-HOME POINTS FROM LECTURES BY CLEVELAND CLINIC AND VISITING FACULTY Rheumatoid arthritis: More aggressive approach improves outlook MICHAEL E. WEINBLATT, MD * Co-director
More informationHOW TO CITE THIS ARTICLE:
EFFICACY OF COMBINATION THERAPY OF METHOTREXATE WITH HYDROXYCHLOROQUINE OR SULFASALAZINE IN RHEUMATOID ARTHRITIS PATIENTS IN KUMAON REGION: A COMPARATIVE STUDY Suyash Bharat 1, Bhavana Srivastava 2, Paramjeet
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationTNF Inhibitors: A New Era in the Treatment of Rheumatoid Arthritis
A Supplement to Rheumatology News I N T E R N A T I O N A L TNF Inhibitors: A New Era in the Treatment of Rheumatoid Arthritis Highlights of a Symposium The Biologic Era: Summary of 5 Years of Experience
More informationDrug combinations with methotrexate to treat rheumatoid arthritis
Drug combinations with methotrexate to treat rheumatoid arthritis T. Rath 1,2 and A. Rubbert 1 1 Department of Internal Medicine I, 2 Institute for Health Economics and Clinical Epidemiology, University
More informationComments from Wyeth on the Assessment Report for the appraisal of Enbrel in RA General Comments
General Comments The TAR economic model is a complex model that attempts to reflect the multiple treatment options and pathways an RA patient can follow. This model demonstrates that it would be cost effective
More informationPrincipal Investigator. General Information. Conflict of Interest. Certification Published on The YODA Project (
Principal Investigator First Name: Liana Last Name: Fraenkel Degree: MD, MPH Primary Affiliation: Yale University School of Medicine E-mail: christine.ramsey@gmail.com Phone number: 610-613-6745 Address:
More informationRheumatoid arthritis in adults: diagnosis and management
National Institute for Health and Care Excellence Consultation Rheumatoid arthritis in adults: diagnosis and management Evidence review F DMARDs NICE guideline CG79 Intervention evidence review January
More informationResearch Article. Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice
Research Article Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice Aim: To evaluate treatment of rheumatoid arthritis with abatacept in the real-life clinic
More informationAssessment group response to Wyeth commentary on assessment report
Assessment group response to Wyeth commentary on assessment report Subject & Wyeth s comments related section/page Model patient The TAR economic model is a complex model that attempts to reflect the population
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationB oth early diagnosis and early treatment with disease
291 RANDOMISED CONTROLLED TRIAL Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled
More informationjournal of medicine The new england Therapies for Active Rheumatoid Arthritis after Methotrexate Failure A BS TR AC T
The new england journal of medicine established in 1812 july 25, 2013 vol. 369 no. 4 Therapies for Active Rheumatoid Arthritis after Methotrexate Failure James R. O Dell, M.D., Ted R. Mikuls, M.D., M.S.P.H.,
More informationA Study on the Selection of DMARDs for the Combination Therapy with Adalimumab
Kobe J. Med. Sci., Vol. 58, No. 2, pp.e41 E50, 2012 A Study on the Selection of DMARDs for the Combination Therapy with Adalimumab CHIHIRO TANAKA 1, KAZUKO SHIOZAWA 2, AKIRA HASHIRAMOTO 1, and SHUNICHI
More informationOverview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission
Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission M.S. Jurgens 1, P.M.J. Welsing 1,2, J.W.G. Jacobs 1 1 Department of Rheumatology and Clinical Immunology,
More informationReview. Margaret Har Yin Ma 1, Andrew P Cope 2 & David L Scott 1,2
Review Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate We evaluated the frequency and type of adverse
More informationG Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report
1 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; 2 Bristol-Myers Squibb, Princeton, New Jersey, USA; 3 Paris-Descartes University, Medicine Faculty and UPRES-EA
More informationΠοώιμη έμαονη ηηπ βιξλξγικήπ θεοαπείαπ ζηη οερμαηξειδή αοθοίηιδα. ΑΝΣΙΛΟΓΟ
Ποώιμη έμαονη ηηπ βιξλξγικήπ θεοαπείαπ ζηη οερμαηξειδή αοθοίηιδα. Τπάοςει επαοκήπ βιβλιξγοαθική ηεκμηοίτζη? ΑΝΣΙΛΟΓΟ Κροιακή Μπξκή Μεζζημία 24-6-2011 ηοαηηγική θεοαπείαπ οερμαηξειδξύπ αοθοίηιδαπ Ποώιμη
More informationAbatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor a Inhibition
The new england journal of medicine original article Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor a Inhibition Mark C. Genovese, M.D., Jean-Claude Becker, M.D., Michael Schiff,
More informationRheumatoid Arthritis. Ajay Bhatia Rheumatology Consultant Hillingdon Hospital
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant Hillingdon Hospital ajay.bhatia@thh.nhs.uk Rheumatoid Arthritis When to refer to secondary care? Why early referral is beneficial for the patient?
More informationT raditional disease modifying antirheumatic drugs
944 EXTENDED REPORT Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study D Aletaha, T Stamm, T Kapral, G Eberl,
More informationEditorial. Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand?
Editorial Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand? M. Govoni 1 and R. Caporali 2 1 Rheumatology Unit, Department of Clinical and Experimental
More informationKeywords Rheumatoid arthritis Infliximab Total van der Heijde Sharp score Joint destruction. Introduction
Mod Rheumatol (2008) 18:447 454 DOI 10.1007/s10165-008-0077-5 ORIGINAL ARTICLE Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management
More informationThe determination and measurement of functional disability in rheumatoid arthritis Frederick Wolfe
The determination and measurement of functional disability in rheumatoid arthritis Frederick Wolfe National Data Bank for Rheumatic Diseases Arthritis Research Center Foundation and University of Kansas
More informationWhat I Have Learned Over the Years - Keystone s Top 10 -
What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,
More informationDiscordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis
Rheumatology Advance Access published August 18, 2008 Rheumatology 2008; 1 of 6 doi:10.1093/rheumatology/ken323 Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid
More informationORIGINAL ARTICLE DANIEL E. FURST, 1 AILEEN L. PANGAN, 2 LESLIE R. HARROLD, 3 HONG CHANG, 4 GEORGE REED, 3 JOEL M. KREMER, 5 AND JEFFREY D.
Arthritis Care & Research Vol. 63, No. 6, June 2011, pp 856 864 DOI 10.1002/acr.20452 2011, American College of Rheumatology ORIGINAL ARTICLE Greater Likelihood of Remission in Rheumatoid Arthritis Patients
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationTreatment of early rheumatoid arthritis
REVIEW Treatment of early rheumatoid arthritis Karim Raza, Mike Salmon & Christopher D Buckley Author for correspondence University of Birmingham, Division of Immunity and Infection, Institute of Biomedical
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationOptimal care for early RA patients: the challenge of translating scientific data into clinical practice
RHEUMATOLOGY Review Rheumatology 2011;50:1194 1200 doi:10.1093/rheumatology/ker131 Advance Access publication 30 March 2011 Optimal care for early RA patients: the challenge of translating scientific data
More informationClinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
1 UZ Gasthuisberg, Leuven, Belgium; 2 Centro Médico Toluca, Metepec, México; 3 Hospital Geral de Goiânia, Goiânia, Brazil; 4 St Augustine s Hospital, Durban, South Africa; 5 Klinikum Eilbek, Hamburg, Germany;
More informationRepair in Rheumatoid Arthritis, Current Status. Report of a Workshop at OMERACT 8
Repair in Rheumatoid Arthritis, Current Status. Report of a Workshop at OMERACT 8 DÉSIRÉE van der HEIJDE, ROBERT LANDEWÉ, JOHN T. SHARP for the OMERACT Subcommittee on Repair ABSTRACT. Repair of structural
More informationO ver many decades disease modifying antirheumatic
63 CONCISE REPORT Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years D Aletaha,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationF. Wolfe 1,2 and K. Michaud 1,3
Rheumatology 2005;44(Suppl. 4):iv18 iv22 Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness
More informationArthritis Research & Therapy 2006, 8:216 (doi: /ar1983)
Review Aspects of early arthritis Definition of disease states in early arthritis: remission versus minimal disease activity Annette HM van der Helm-van Mil, Ferdinand C Breedveld and Tom WJ Huizinga Department
More informationUtility of disease modifying antirheumatic drugs in sawtooth strategy. A prospective study of early rheumatoid arthritis patients up to 15 years
68 Ann Rheum Dis 999;58:68 622 EXTENDED REPORTS Department of Medicine, Jyväskylä Central Hospital, Keskussairaalantie 9, FIN 462 Jyväskylä, Finland Correspondence to: Dr T Sokka. Accepted for publication
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationKey Words: Rheumatoid Arthritis, etanercept, post-marketing study, comparative study
CLINICAL DATA GAP BETWEEN PHASE III CLINICAL TRIALS (PRE-MARKETING) AND PHASE IV (POST-MARKETING) STUDIES: EVALUATION OF ETANERCEPT IN RHEUMATOID ARTHRITIS Pendar Farahani 1,3, Mitchell Levine 1,2, Kathryn
More informationOPEN ACCESS EXTENDED REPORT. Clinical and epidemiological research
OPEN ACCESS 1 Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 2 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands 3 Department
More informationN J Wiles, D G I Scott, E M Barrett, P Merry, E Arie, K GaVney, A J Silman,
Ann Rheum Dis ;: ARC Epidemiology Unit, University of Manchester Medical School, Oxford Road, Manchester M PT, UK N J Wiles A J Silman D P M Symmons Department of Rheumatology, Norfolk and Norwich Hospital,
More informationAmalia A. van Everdingen, MD; Johannes W.G. Jacobs, MD, PhD; Dirk R. Siewertsz van Reesema, MD; and Johannes W.J. Bijlsma, MD, PhD
Annals of Internal Medicine Article Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects A Randomized, Double-Blind,
More informationPreventing the Progression From Undifferentiated Arthritis to Rheumatoid Arthritis: The Clinical and Economic Implications
n report n Preventing the Progression From Undifferentiated Arthritis to Rheumatoid Arthritis: The Clinical and Economic Implications Michael H. Schiff, MD Introduction Over the past few years, the management
More informationCHAPTER 4. S. Hirata 1, 2 L. Dirven 1 Y. Shen 3 M. Centola 4 G. Cavet 3 W.F. Lems 5 Y. Tanaka 2 T.W.J. Huizinga 1 C.F. Allaart 1
CHAPTER 4. A multi-biomarker based disease activity (MBDA) score system compared to a conventional disease activity score (DAS) system in the BeSt rheumatoid arthritis (RA) study S. Hirata 1, 2 L. Dirven
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationJohannes W. G. Jacobs Johannes W. J. Bijlsma AN UPDATE OF GLUCOCORTICOID THERAPY IN RHEUMATOID ARTHRITIS: DO BENEFITS OUTWEIGH THE RISKS?
AN UPDATE OF GLUCOCORTICOID THERAPY IN RHEUMATOID ARTHRITIS: DO BENEFITS OUTWEIGH THE RISKS? Johannes W. G. Jacobs Johannes W. J. Bijlsma University Medical Center Utrecht,The Netherlands. ABSTRACT To
More informationRESEARCH ARTICLE. Yang Liu 1, 3, Wei Fan 2, Hao Chen 2, Ming-Xia Yu 2 * Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.8.3403 Risk of Cancer in Rheumatoid Arthritis Patients Undergoing TNF-α Antagonists Therapy: a Meta-Analysis RESEARCH ARTICLE Risk of Breast Cancer and Total
More informationMethotrexate (MTX) has become the anchor
S9 Update on Methotrexate as the Anchor Drug for Rheumatoid Arthritis Theodore Pincus, M.D., Kathryn A. Gibson, M.D., Ph.D., and Isabel Castrejón, M.D. Abstract Methotrexate has become the anchor drug
More informationCover Page. The following handle holds various files of this Leiden University dissertation:
Cover Page The following handle holds various files of this Leiden University dissertation: http://hdl.handle.net/1887/58878 Author: Akdemir, G. Title: Improving targeted treatment in early rheumatoid
More informationCohen: Well, hi to my listeners, this is Dr. Marc Cohen, and I am happy again to discuss with you advances in the efficacy and safety of TNF
Cohen: Well, hi to my listeners, this is Dr. Marc Cohen, and I am happy again to discuss with you advances in the efficacy and safety of TNF inhibitors. This is a subject of great interest to me and I
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationEffectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials
Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials K. Martin 1, F. Bentaberry 2, C. Dumoulin 2, J. Dehais 2, F. Haramburu 1, B. Bégaud
More information